Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Exact

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.

A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

Investors Business Daily

Exact Sciences Stock Drops 11% Over Four Days. 'What Is Going On?'

Exact Sciences stock crumbled Thursday on its growing rivalry with Guardant Health and Natera in colon cancer screening.

Investors Business Daily

Why Exact Sciences, Up 27%, Is 'Coiled To Snap Back' After Quarterly Beat

Exact Sciences stock bounded higher Thursday after beating second-quarter expectations, signaling a return to growth for Cologuard.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Cathie Wood Darling Exact Sciences, And Rival Guardant Health, Dip On Colon Cancer Updates

Exact Sciences stock fell early Thursday after the company said its next-generation Cologuard beat a rival stool-based screening test.

Investors Business Daily

Exact Sciences, A Cathie Wood Holding, Comes In Hot With Double-Digit Sales Growth

Exact Sciences, a large Cathie Wood holding, came in hot with double-digit sales growth. But EXAS stock reversed lower.

Investors Business Daily

The Wild Ride That Has Sent Exact Sciences 216% Higher Since October

Exact Sciences said the company's next-generation Cologuard outperformed the original test. EXAS stock seesawed on the news.

Investors Business Daily

Why Top 2% Stock Exact Sciences Is On An Eight-Month Hot Streak — And Just Hit A Profit-Taking Zone

The market for colon cancer screening is massive — and underserved. And that might be why EXAS stock is on an eight-month hot streak.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Exact Sciences, Guardant Health Put Up Big Sales Beats As They Target The 'Most Preventable' Cancer

Exact Sciences delivered a first-quarter report that "checked all the boxes," an analyst said as EXAS stock surged.

Investors Business Daily

Exact Sciences, A Top 5% Stock, Beat Quarterly Expectations

Exact Sciences delivered a second consecutive quarter of sales growth acceleration and EXAS stock rose on Wednesday.

Investors Business Daily

Cathie Wood Is Crushing It This Year Thanks To 9 Stocks

Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.

Investors Business Daily

Exact Sciences Surges After Massively Beating Quarterly Forecasts, Raising Outlook

Exact Sciences massively beat third-quarter expectations and raised its full-year outlook — and EXAS stock skyrocketed on Friday.

Investors Business Daily

SVB Leerink Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know

SVB Leerink has decided to maintain its Outperform rating of Exact Sciences (NASDAQ:EXAS) and lower its price target from $130.00 to $95.00. Shares of Exact Sciences are trading up 7.86% over the last 24 hours, at $63.24 per share.

Benzinga

Non-COVID Sales Boost Exact Sciences' Q1 Revenue; Revises FY22 Guidance

Exact Sciences Corp's (NASDAQ:EXAS) Q1 revenues increased 21% Y/Y to $486.6 million, beating the average Wall Street estimate of $461.71 million. Excluding COVID-19 testing revenues, which dropped 15% to $27.4 million, Exact's Q1 revenue increased 24%. Screening revenues rose 28% to $306.5 million in Q1, while Precision Oncology revenues were up 18%…

Benzinga

Exact Sciences Clocks 16% Jump In Q4 Non-COVID-19 Revenues

Exact Sciences Corp's (NASDAQ: EXAS) Q4 revenues increas

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Communication Services

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.